COPD
Conditions
Keywords
COPD; GP Surgeries
Brief summary
This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices.
Detailed description
This study will look at the impact of care delivery by a specialist respiratory doctor compared to general practitioners for patients with COPD in East Birmingham. It will be run from the Heart of England NHS Foundation Trust, which will provide the specialist input and oversight, and up to 40 practices across the Eastern Birmingham Health Organisation with approximately 2200 patients with COPD confirmed by their current medical practitioner. Each practice will be randomised to either the intervention or control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. Treatment will be at the discretion of the clinician and is not specified in the trial protocol. The investigators anticipate that the treatment recommendations in the intervention arm may include referral to pulmonary rehabilitation and reduction in the use of inhaled corticosteroids, which are prescribed at high rates in our locality. The control group will be seen by the usual staff at their practice. These patients will not be seen by the trial team and their data will be extracted remotely using electronic systems. The primary outcome will be to compare the rates of provision of guideline-based care in intervention and control practices. Secondary outcomes will include: referral to secondary care, unscheduled healthcare consultations (ED attendance, hospital admissions), COPD exacerbations, healthcare costs, medications prescribed, biochemical markers of disease, radiological investigations, lung function tests measured when clinically indicated, and death within 12 month follow-up period.
Interventions
BEHAVIORALIntervention Arm
The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
BEHAVIORALControl Arm
Usual standard of care
Sponsors
AstraZeneca
Heart of England NHS Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
There are two groups: An intervention group and a control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. The control group will receive the usual standard of care.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Practices will be eligible for inclusion if they give consent to data collection and are part of the EBHO. * Patients from the practices will be eligible if they are coded to have COPD within the GP record. In addition patients who are not coded to have COPD in the GP record, but who have a hospital admission with a primary diagnosis of COPD within the enrolment period for practices (first 3 months) will be eligible.
Exclusion criteria
• Patients will only be excluded if they are proven not to have COPD at specialist assessment, or during the follow up period, as determined by changes in medical coding within the GP record. If patients are assessed by the specialist and the diagnosis is not felt to be robust, enrolment will be suspended until this matter can be clarified by use of post bronchodilator spirometry and/or other required parts of their clinical care.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rates of provision of guideline-based care in intervention and control practices for patients. | 1 Year | This will be done via the number of patients concordant with local guidelines (where care is defined by medication received and non-pharmacological interventions received, and they must receive smoking cessation, pulmonary rehabilitation, self-management plan and appropriate COPD medications in order to be guideline compliant) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Unscheduled Outcome | 1 Year | Unscheduled healthcare consultations (ED attendance, hospital admissions) |
| COPD Outcomes | 1 Year | COPD exacerbations |
| Healthcare Outcomes | 1 Year | mean cost per patient in £ of the total cost of hospital attendances, GP visits, medications and vaccines during the study period |
| Medications Outcomes | 1 Year | medications prescribed |
| Referral Outcome | 1 Year | Referral to secondary care |
| Radiological Outcomes | 1 Year | number of CT scans or Chest X rays done |
| Lung Function Outcomes | 1 Year | Lung function tests measured when clinically indicated, FEV1 (l) and FEV1 (% predicted), FEV1/FVC |
| Death Outcome | 1 Year | Death within 12 month follow-up |
| Biochemical markers of disease Outcomes | 1 Year | FBC, U&E, LFT, CRP, AAT level/phenotype, and sputum culture results taken for patient |
Countries
United Kingdom
Outcome results
None listed